Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces the appointment of Dr Simon Douglas as independent Non-Executive Chairman.
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces its unaudited interim results for the six months ended 30 September 2020 in line with the trading update announced at the end of October. The Company also provides an update on the core business and the Board’s expectation for a significantly improved performance in the second half.
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, provides the following update to shareholders covering:
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing provides the following trading update in advance of its final results for the year ended 31 March 2020 and an impact assessment of the coronavirus global pandemic.
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces its unaudited interim results for the six months ended 30 September 2019.
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following trading update for the six months to 30 September 2019, in advance of releasing its interim results on Monday 2 December 2019.
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces its audited results for the year ended 31 March 2019.
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announcesthat results for the year ended 31 March 2019 will be in line with market expectations.
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the appointment of Jeremy Millard as Non-Executive Director to the Board with immediate effect, after a thorough search process.
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces its unaudited interim results for the six months ended 30 September 2018.